This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Invitrogen announced this week that it had reached an agreement to sell its long-struggling BioReliance unit to private equity firm Avista Capital Partners for approximately $210 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.